[1]李兆申.胆胰疾病介入治疗现状与展望[J].中国实用内科杂志, 2006, 26 (10) :798-799.
|
[2]陈筠, 王世明, 马艳波, 等.三镜联合治疗胆道结石的体会[J].山西医科大学学报, 2006, 37 (9) :961-962.
|
[3]朱湘南, 蒋柯, 宁国强, 等.三镜不同组合微创治疗胆囊结石并肝外胆管结石[J].实用临床医学, 2008, 9 (12) :62-63.
|
[4] 中华医学会消化内镜分会ERCP学组.ERCP诊治指南 (2010版) [J].中华消化内镜杂志, 2010, 27 (3) :113-117.
|
[5]吕忠, 程云霄, 葛敦钧, 等.“三镜七法”治疗肝外胆道结石246例分析[J].中国微创外科杂志, 2007, 7 (9) :858-860.
|
[6]庞志东.三镜联合微创治疗胆囊结石合并胆总管结石[J].微创医学, 2009, 4 (5) :474-476.
|
[1] | Yu LIANG, Yuanhong ZHAO, Zheng LI. Recent advancement in research on intrahepatic cholangiocarcinoma: Risk factors and pathogenesis[J]. Journal of Clinical Hepatology, 2022, 38(10): 2391-2395. doi: 10.3969/j.issn.1001-5256.2022.10.037 |
[2] | Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048 |
[3] | Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043 |
[4] | Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044 |
[5] | Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041 |
[6] | Bai Xue, Ma ZuoHong, Hao ZhiQiang, Fu XiBo, Jiao Ao, Shang Hai, Hua XiangDong. Research advances in the risk factors for microvascular invasion in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(11): 2578-2581. doi: 10.3969/j.issn.1001-5256.2019.11.042 |
[7] | Liu HongJin, Bao ChunMei, Bai WenLin, Li YinYin, Rong GuangHua, Lu YinYing, Chen Yan, Liu Ze, Cheng JiaMin, Ceng Zhen. Risk factors for infectious complications in primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1033-1037. doi: 10.3969/j.issn.1001-5256.2018.05.021 |
[8] | Chang XiuJuan, Lu YinYing, Rong GuangHua, Liu Ze, Chen Yan, Xu GuiLin, Gao XuDong, Lou Min, Wang ChunPing, Yang YongPing, Ceng Zhen. Risk factors for vascular invasion of primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1038-1041. doi: 10.3969/j.issn.1001-5256.2018.05.022 |
[9] | Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022 |
[10] | Ai YeQing, Zhang ChengHua, Liu HuiFang. Risk factors for postoperative pulmonary infection in patients with primary liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(7): 1334-1337. doi: 10.3969/j.issn.1001-5256.2016.07.024 |
[11] | Qiao LiNa, Dai GuangRong, Zhang Jin, Shen Ni. An epidemiological survey of prevalence and risk factors for fatty liver disease in adults residing in Yan'an,China[J]. Journal of Clinical Hepatology, 2015, 31(1): 82-87. doi: 10.3969/j.issn.1001-5256.2015.01.018 |
[12] | Chen BiHua, Zhang Wei, Wu Pei, Huang Ying. Research advances in risk factors for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2088-2092. doi: 10.3969/j.issn.1001-5256.2015.12.024 |
[13] | Hu CaiXia, Zheng JiaSheng, Lin Wei, Cui ShiChang. Analysis of risk factors for early recurrence after microwave ablation for primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(2): 228-231. doi: 10.3969/j.issn.1001-5256.2015.020 |
[14] | Gao Rui, Liu ZhongJing, Chen Fei, Gao Lei, Jiang ChuanWu. Multivariate regression analysis of risk factors for HBV-related primary liver cancer[J]. Journal of Clinical Hepatology, 2014, 30(4): 370-372. doi: 10.3969/j.issn.1001-5256.2014.04.021 |
[15] | Yu Zheng, Jia JiDong. Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury[J]. Journal of Clinical Hepatology, 2013, 29(9): 674-677. doi: 10.3969/j.issn.1001-5256.2013.09.010 |
[16] | Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304. |
[17] | Liu HongHong, Fu JunLiang, Fu BaoYun, Zhang Zheng, Xu RuoNan, Luo ShengQiang, Shi Ming, Li YongGang, Wang FuSheng. The pathogenesis and risk factors related to prognosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(2): 153-155. |
[18] | Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102. |